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Abstract
Background: Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor
that belongs to the nuclear hormone receptor superfamily. PPARγ is essential in adipocyte differentiation from
precursor cells. Its antitumorigenic effects are reported in certain malignancies; however, its effects in liposarcoma
are unclear.
Methods: We analyzed PPARγ expression using immunohistochemistry (IHC) in 46 patients with myxoid liposarcoma
[MLS; median age, 47 years (range, 14–90 years) and mean follow-up period, 91 months (range, 13–358 months)].
PPARγ mRNA expression levels were measured by quantitative reverse transcription polymerase chain reaction. Further,
we evaluated the correlation of PPARγ expression with clinical outcomes.
Results: We found that the metastasis-free survival rate was significantly higher in lower PPARγ expressers [34 patients
with labeling index (LI) <50 %] than in higher expressers (12 patients with LI ≥50 %; p = 0.01). Cox multivariate analysis
revealed that a higher PPARγ level was an independent predictor of metastasis (relative risk = 6.945, p = 0.026).
Furthermore, using 28 fresh MLS specimens, we confirmed an increased PPARγ mRNA expression level in the higher
LI group (p = 0.001).
Conclusions: In this study, higher PPARγ expression in MLS was a risk factor associated with distant metastasis;
therefore, it would be a novel prognostic marker for MLS. Further analyses will help to understand the correlation
between PPARγ expression and tumor malignancy in liposarcoma.
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Background
Liposarcoma is one of the most common adult soft tis-
sue sarcomas, accounting for 15–20 % of all sarcomas
[1]. It is histologically classified into 3 subtypes: dediffer-
entiated, myxoid, and pleomorphic liposarcomas. Of
these, myxoid liposarcoma (MLS) accounts for one-third
to one-half of liposarcomas [2]. A diagnostic nomencla-
ture of “round cell liposarcoma” was used when the
round cell component of MLS tissues was >5 % [3].
However, MLS and round cell liposarcoma were found
to represent the same entity because they share a key
chromosomal translocation t(12;16)(q13;p11), generating
a fusion oncogene FUS-DDIT3 [4, 5]. Recent evidence
has indicated that the activation of PI3K/Akt pathway
via activating mutation of PIK3CA, loss of PTEN, or
IGF1R expression would have a role in round cell trans-
formation [6]. Although MLS is considered to be a low-
to-intermediate grade malignancy [1], distant metastasis
of the tumor cells may occasionally occur. It is currently
believed that a proportion of round cells is an estab-
lished predictor of clinical outcome in patients with
MLS. For example, MLS containing >10 % of round cells
may indicate poor prognosis because of the high risk of
* Correspondence: a_take@med.kanazawa-u.ac.jp
1Department of Orthopaedic Surgery, Kanazawa University Graduate School
of Medical Sciences, 13-1 Takara-machi, Kanazawa 920-8641, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Takeuchi et al. BMC Cancer  (2016) 16:442 
DOI 10.1186/s12885-016-2524-6
metastasis occurrence [1]. However, there is yet no con-
sensus regarding the percentage of round cells that
would help in the grading of MLS. Furthermore, the
benefit of chemotherapy is yet controversial in the
treatment of MLS [7, 8]. Therefore, additional and/or
stronger prognostic markers are required to accurately
predict prognosis and to develop effective therapeutic
strategies for patients with MLS.
Peroxisome proliferator-activated receptor gamma
(PPARγ) is a master regulator of adipocyte differenti-
ation [9] and is expressed in various types of cancers,
such as breast [10], colon [11], prostate [12], thyroid
cancers [13], and giant cell tumor of bone [14]. A signifi-
cant elevation in PPARγ expression was reported in
MLS, pleomorphic liposarcoma, and dedifferentiated
liposarcoma, particularly in differentiated areas of dedif-
ferentiated liposarcoma, compared with lipoma or well-
differentiated liposarcoma [15]. However, a correlation
between PPARγ expression and clinical outcomes of
MLS has not been yet completely elucidated. Therefore,
this study aimed to evaluate PPARγ expression in MLS
and elucidate whether PPARγ expression could be a
prognostic biomarker in the recurrence and metastases
of MLS.
Methods
Patients and tumor specimens
Patients with MLS were enrolled by searching the hos-
pital computer database, to find who had been treated at
the Department of Orthopaedic Surgery in Kanazawa
University Hospital between 1989 and 2012. Forty-six
patients with MLS comprised the cohort of the current
study. The median age was 47 years (range, 14–90
years), and the mean follow-up period was 91 months
(range, 13–358 months). Thirty-eight patients had pri-
mary lesions, and 8 patients presented with recurrent tu-
mors. According to the American Joint Committee on
Cancer classification [16], 9, 2, and 35 patients were
classified as stage IIA, IIB, and III, respectively. The pri-
mary tumor sites were in the upper extremity (2 cases),
lower extremity (38 cases), and axial location (6 cases).
Thirty-eight patients had no round cell component.
Seven tumors contained <5 % of the round cell compo-
nent and only 1 tumor showed >5 % of the round cell
component. Paraffin-embedded tissue specimens of sur-
gical resected primary or recurrent tumors from the
current 46 patients and 28 of 46 frozen tumor specimens
were available for immunohistochemistry (IHC) and
quantitative reverse transcription (RT)-polymerase chain
reaction (PCR) analyses, respectively. The study was ap-
proved by the Ethics Committee for Medical Studies at
the Kanazawa University Graduate School of Medical
Sciences.
Immunohistochemical analysis and scoring
Tissue specimens were fixed in 20 % formalin and em-
bedded in paraffin. They were retrieved from the surgi-
cal pathology files of the Pathology Section of Kanazawa
University Hospital (Kanazawa, Japan). For each case,
one representative block of formalin-fixed and paraffin-
embedded tumor tissue was selected. All sections were
cut at 4-μm thickness for IHC. A mouse monoclonal
antibody against PPARγ (1:250, sc-7273, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was used as the
primary antibody and anti-mouse IgG conjugated with
peroxidase-labeled polymers (EnVision, Dako, Carpin-
teria, CA, USA) was used as a secondary antibody. After
visualization of the reaction product, sections were
counterstained with Meyer’s hematoxylin and cover-
slipped for microscopic observation. Apparent brown
stains were considered to be immunopositive spots.
Negative controls were used by excluding the primary
antibody. All positive and negative cells were counted in
a minimum of 5 non-overlapping visual fields at 200×
magnification. The labeling index (LI) for PPARγ was
calculated as the percentage of positive cells among the
total number of cells counted, which was at least 250
tumor cells [17]. LI was performed by two assessors (AT
and SM) blinded to patient outcome and the assessment
was duplicated. With this evaluation, we categorized
higher and lower PPARγ expressers as those with >
and <50 % of LI, respectively.
Real-time reverse transcription polymerase chain reaction
Twenty-eight frozen tumor tissues were available for
real-time RT-PCR analysis. Total mRNA was isolated
using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. The quan-
tity of RNA was measured using the NanoDrop lite
(Thermo Fisher Scientific Inc., Waltham, MA, USA).
First-strand cDNA was generated from total RNA using
the QuantiTect Reverse Transcription Kit (Qiagen) with a
poly (dT) oligonucleotide primer. PPARγ (QT00029841)
and GAPDH (QT01192646) primers were purchased from
Qiagen. Real-time PCR was performed using QuantiFast
SYBR Green PCR Kit (Qiagen) and Stratagene Mx3000P
QPCR System (Agilent Technologies, La Jolla, CA, USA).
The relative mRNA expression level was calculated using
a comparative Ct (ΔCt) method with LinReg PCR software
(http://LinRegPCR.nl).
Statistical analysis
Statistical analysis was performed using SPSS v.19.0
(SPSS Inc., Chicago, IL, USA). Correlation of the PPARγ
LI with patient prognosis and histological subtype (pure
type vs. round cell group) was evaluated using the chi
square test. The following demographic and treatment
factors were examined for prognostic importance:
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patient age, sex, tumor site (extremity or axial), tumor
size, patient status (primary or recurrence), presence
of round cell component, surgical margin, chemother-
apy, radiotherapy, and PPARγ LI. The association of
each factor with subsequent tumor recurrence and
distant metastasis was analyzed using the log-rank
test and Cox proportional hazards regression analysis
using backward step-by-step exclusion. In Cox pro-
portional hazards models, the factors with p < 0.3 in
univariate analysis were included. The relative PPARγ
mRNA and protein expressions were statistically evaluated
using Student’s t-test. For each test, results were consid-
ered statistically significant whenever a probability (p)
value <0.05 was achieved.
Results
We first examined the correlation between the clinical
outcomes and PPARγ expression by IHC in tumors from
patients with MLS. Positive signals for PPARγ were ob-
tained in the nucleus of the tumor cells (Fig. 1a). The
higher (LI ≥50 %) and lower (LI <50 %) expressions of
PPARγ were observed in the specimens from 12 and 34
patients with MLS (Fig. 1a, b), respectively. Among the
34 samples, an absence of PPARγ expression in the
tumor was demonstrated in 5 MLS patients. We con-
firmed PPARγ mRNA expression levels by quantitative
RT-PCR. The relative PPARγ mRNA levels were found
to be 3.48 vs 2.13 in tumors in patients with higher vs
lower PPARγ expression by IHC, respectively (p = 0.001;
Fig. 2). Chi square analysis showed that PPARγ expres-
sion was not significantly associated with patient status
of MLS recurrence (p = 0.178; Table 1). Among 8 pa-
tients with MLS with the round cell component, 4 pa-
tients were found to be higher expressers of PPARγ and
the remaining 4 had lower PPARγ expression (Table 2).
Furthermore, in the group with no round cells, 8 pa-
tients had higher PPARγ expression and the remaining
30 patients had lower expression. However, there were
no statistically significant differences in PPARγ expres-
sion between the 2 groups (p = 0.178; Table 2). Most
patients with round cells showed positivity for PPARγ
(Fig. 1a). Local recurrence occurred in 9/46 (19.6 %) pa-
tients with MLS at our institute (Table 3). Time to local
recurrence varied from 10 to 72 months. In a univariate
analysis, extremity of the MLS sites (p = 0.001), primary
tumor (p < 0.001) and negative surgical margin (p =
0.001) significantly correlated with a better recurrence-
free survival (Table 3). The 5-year local recurrence-free
survival rate was 83.8 and 67.5 % in the PPARγ lower
and higher expressers, respectively (Table 3). However,
PPARγ expression level was not significantly associated
with local recurrence (p = 0.327; Fig. 3a). Using a multi-
variate analysis, no independent factors were associated
with local recurrence. In a total of 46 patients with MLS,
6 (13.0 %) cases developed distant metastasis (Table3),
and the time course to distant metastasis varied from 4
to 74 months. The sites of metastases of MLS included
the spine (2 cases), the femur (1 case), the retroperito-
neum (1 case), the axilla (1 case), and the lung (1 case).
The 5-year distant metastasis-free survival rates were
94.1 and 70.1 % in PPARγ lower and higher expresser
groups, respectively (Table 3), and there was a statisti-
cally significant difference between the lower and higher
groups (p = 0.01; Fig. 3b). High PPARγ expression was
an independent risk factor of distant metastasis of MLS
using a multivariate analysis (HR, 6.945; 95 % CI, 1.265–
38.15, p = 0.026; Table 4). In this study, we could not
identify any positive prognostic factors for overall sur-
vival using either univariate or multivariate analyses in
patients with MLS whose overall cumulative 5- and 10-
year survival rates were 97.4 and 92.3 %, respectively
(Table 3, Fig. 4).
Discussion
In the present study, we examined the PPARγ expression
in tumor cells of patients with MLS by IHC and
confirmed PPARγ mRNA expression levels using
quantitative RT-PCR (Fig. 2). We found that PPARγ
expression in tumors was significantly associated with
the development of distant metastasis, but was not
Fig. 1 a Higher PPARγ expression was observed using immunohistochemistry [IHC; labeling index (LI) ≥50 %]. Positive signals were detected in
the nucleus. This section contains a round cell component and most round cells were positive for PPARγ (black arrow head). b Lower PPARγ
expression (LI <50 %). The scale bar corresponds to 200 μm
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correlated with recurrence-free or overall survival, in pa-
tients with MLS (Fig. 3, Tables 3 and 4). Therefore, we
suggest that high PPARγ expression could be a novel
risk factor for distant metastasis of MLS.
Tontonoz et al. first reported that PPARγ- and retinoid
X receptor-specific ligands stimulated cellular differenti-
ation in liposarcoma cells [18]. In another study, Tajima
et al. reported higher PPARγ expression observed in
MLS, pleomorphic liposarcoma, dedifferentiated liposar-
coma, and the differentiated area of dedifferentiated lipo-
sarcoma compared with lipoma and well-differentiated
liposarcoma by IHC [15]. However, the correlation and
significance of PPARγ expression and clinical out-
comes in patients with MLS have not yet been com-
pletely evaluated.
In the present study, the incidence of local recurrence
of MLS was 19.6 %, which is in the range from 8 to 33 %
demonstrated in other reports [3, 18, 19]. In addition,
the incidence of distant metastasis in this study was
13.0 %, and this value was within previously reported
ranges from 10 to 38 % [19, 20]. It is reported that
potential risk factors for clinical outcomes in pa-
tients with MLS are (1) tumor size (>10 cm) [21],
(2) age (>45 years) [20, 21], (3) presence of the
round cell component [2], and (4) non-extremity le-
sions [20]. In our study, univariate analysis showed
that extremity lesion site of the tumor significantly
correlated with a better recurrence-free and overall
survival (Table 3). However, we could not find any
statistically significant correlations using the multivariate
analysis. However, PPARγ expression was significantly as-
sociated with the distant metastasis-free survival rate
by both the univariate (p = 0.01; Table 3) and multi-
variate (p = 0.041; Table 4) analyses.
Fig. 2 PPARγ mRNA expression levels. The relative PPARγ mRNA expression in the specimens from patients with higher PPARγ expression
(LI ≥50 %) was 3.48 ± 0.29 (the mean and standard error). The value of lower PPARγ expression (LI <50 %) was 2.13 ± 0.20. There was a significant
difference in PPARγ mRNA levels between the two groups (p = 0.001). Dashed lines represent the mean value
Table 1 Chi-square analysis of PPARγ with status
Primary Recurrence p value
PPARγ low (LI < 50 %) 30 4
high (LI≥ 50 %) 8 4 p = 0.178
Table 2 Chi-square analysis of PPARγ with or without round cell
component
No round cell Round cell p value
PPARγ low (LI < 50 %) 30 4
high (LI ≥ 50 %) 8 4 p = 0.178
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MLS metastases to extrapulmonary sites have been re-
ported in some cases [22]. In this study, 5 of 6 patients
developed extrapulmonary site metastasis including the
spine (2 cases), the femur (1 case), the retroperitoneum
(1 case) and the axilla (1 case). However, the disease-
specific deaths occurred only in 2 patients with spine or
femur metastasis, which seemed to be a better survival
rate when compared to previous reports. Asano et al. re-
ported that the low histological grade was significantly
associated with extrapulmonary metastasis [23]. They
also reported that the overall survival rate was sig-
nificantly better for patients with extrapulmonary
metastases (63 %) compared to those with pulmon-
ary metastases (0 %) [23].
PPARγ is reported to possess an antitumor activity
through the suppression of tumor proliferation and
invasion [24] and the induction of differentiation and
apoptosis in cancer cells [25]. Therefore, we initially hy-
pothesized that less PPARγ expression may be associated
with an aggressive behavior or a shorter survival rate in
patients with MLS, which is closely associated with
adipocyte differentiation. However, the results were
contradictory to our initial expectation. Lower PPARγ
expression was significantly associated with being free
from distant metastasis of MLS (Table 3, Fig. 3b). Thus,
it is yet unknown which molecular mechanisms influ-
ence PPARγ expression on MLS tumor malignancy.
With regard to our data, higher PPARγ expression is
Table 3 Univariate analysis of prognostic factors
Factors No. of patients (event) 5-y RFS p value No. of patients (event) 5-y MFS p value No. of patients (event) 5-y OS p value
Overall 46 (9) 46 (6) 46 (2)
Age
<45 y.o. 20 (6) .739 .164 20 (2) .900 .605 20 (1) .947 .877
≥45 y.o. 26 (3) .869 26 (4) .873 26 (1) 1.000
Gender
Male 28 (8) .736 .101 28 (4) .888 .898 28 (2) .962 .264
Female 18 (1) .933 18 (2) .889 18 (0) 1
Site
Extremity 42 (6) .839 .001 42 (5) .898 .479 42 (1) 1 .045
Axial 4 (3) .500 4 (1) .750 4 (1) .750
Size
<10 cm 21 (4) .800 .797 21 (2) .950 .437 21 (1) 1.000 .857
≥10 cm 25 (5) .821 25 (4) .836 25 (1) .950
Status
Primary 38 (4) .886 <.001 38 (4) .892 .378 38 (1) .970 .268
Recurrent 8 (5) .429 8 (2) .857 8 (1) 1.000
Round cell
No 38 (6) .856 .092 38 (4) .921 .216 38 (2) .970 .551
Yes 8 (3) .571 8 (2) .686 8 (0) 1
Surgical margin
Negative 39 (4) .884 <.001 39 (4) .922 .248 39 (1) 1 .216
Positive 7 (5) .429 7 (2) .714 7 (1) .857
Chemotherapy
No 32 (8) .758 .173 32 (5) .867 .485 32 (2) .964 .359
Yes 14 (1) .917 14 (1) .929 14 (0) 1
Radiotherapy
No 41 (8) .811 .846 41 (6) .870 .361 41 (2) .971 .629
Yes 5 (1) .800 5 (0) 1 5 (0) 1
PPARγ
low (LI < 50 %) 34 (6) .845 .327 34 (2) .941 .010 34 (1) .968 .383
high (LI ≥ 50 %) 12 (3) .675 12 (4) .707 12 (1) 1
RFS recurrence-free survival, MFS metastasis-free survival, OS disease specific overall survival
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correlated with shorter survival in pancreatic ductal
adenocarcinoma [26] and prostate cancer [27] and with
the onset and progression of ovarian cancer [28]. Syn-
thetic PPARγ stimulators such as thiazolidinediones
(TZDs) are widely used for the treatment of patients
with type 2 diabetes mellitus [29]. TZDs have been used
to treat liposarcoma patients; however, some clinical tri-
als failed to show favorable results [18, 30, 31]. Experi-
mentally, Pérez-Losada et al. showed the induction of
liposarcomas in FUS-DDIT3 transgenic mice [32]. Al-
though PPARγ expression was significantly expressed in
the tumor, adipocytic development was inhibited [32].
Thus, the authors speculated that the downstream sig-
naling of PPARγ in tumor cells would be specifically
dysregulated by the FUS-DDIT3 transgene even at
higher PPARγ levels [32]. Therefore, the upregulation of
PPARγ expression may be caused by the blockade of
downstream signaling of PPARγ in MLS cells. The
higher expressers would then be categorized as a malig-
nant phenotype with distant metastasis in MLS. Further
detailed studies are required to reveal this possibility.
Recently, a novel drug, trabectedin, was developed and
introduced as chemotherapy for patients with MLS
showing favorable effects [33]. The drug is reported to
induce the maturation of MLS lipoblasts in vivo by tar-
geting the FUS-DDIT3 chimera [34], thus possibly pre-
venting the inhibition of PPARγ signaling. In a phase II
clinical trial study of trabectedin for advanced MLS,
Gronchi et al. showed that 7 of 29 patients achieved par-
tial response (objective response rate, 24 %; 95 % CI,
10–44 %) [33]. These accumulating data suggest that the
PPARγ signaling pathway could be important for car-
cinogenesis, cell differentiation, and the biology under-
lying MLS.
Demicco et al. reported the data about the activa-
tion of PI3K/Akt pathway and mutation analysis of
PIK3CA in MLS, suggesting the link to round cell
change. [6]. Guo et al. reported that PI-103, a dual
PI3K/mTOR inhibitor, effectively inhibited the activa-
tion of the PI3K/Akt in liposarcoma cell lines and
induced apoptosis. In addition, the combination of PI-
103 with doxorubicin and cisplatin demonstrated
strong synergized the growth-inhibitory effect [35].
These findings also suggest that the PI3K/Akt path-
way could play a role in malignant phenotype forma-
tion of MLS.
Fig. 3 a Recurrence-free survival rate. There were no significant differences in recurrence-free survival between patients with higher and lower
PPARγ expression (p = 0.327). b Metastasis-free survival rate. Metastasis-free survival rate was significantly higher in patients with lower PPARγ
expression than in those with higher PPARγ expression (p = 0.01)
Table 4 Cox proportional hazards regression analysis of factor affecting metastasis-free survival













95 % CI p value
Round cell 0.005 0.08 1.083 0.129–9.084 0.941
Surgical margin (positive) 1.588 1.321 3.746 0.480–29.228 0.208
High PPARγ expression (LI≥ 50 %) 4.791 2.119 8.327 1.248–55.55 0.029 4.972 1.938 6.945 1.265–38.15 0.026
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This study has some limitations. First, this is a retro-
spective study with only a small number of patients
enrolled and only one tumor having a >5 % round cell
component. Second, there was heterogeneity in the
treatment, including different modalities such as surgery,
chemotherapy, radiotherapy, and their combinations.
The treatment strategy varied depending on the pres-
ence of a round cell component, tumor size and loca-
tion, and surgical margin.
Conclusions
Our findings showed that high PPARγ expression was
significantly associated with the presence of distant me-
tastasis in patients with MLS. PPARγ expression may be
a putative novel prognostic marker of MLS. Further in-
vestigations are necessary to confirm our findings and
reveal the underlying mechanistic correlation between
PPARγ and MLS malignancy.
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